Tata 1mg and Vitonnix UK get into an exclusive partnership in India

Launch innovative vitamin sublingual sprays

Merck to acquire Harpoon Therapeutics for US$ 680 million

Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors

Arco Lab acquires an additional 25% stake in Neviton at Rs. 9.22 Cr

Arco Lab now holds a 50% stake in Neviton

Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer

This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.

Dr. Reddy's acquires MenoLabs

Qure solidifies its position as innovation powerhouse with 26 patents

Marks remarkable acceleration in innovation using AI technology

Innovent Biologics, Xuanzhu collaborate on clinical trial for advanced solid tumors in China

Innovent will supply sintilimab for the collaborated clinical trial

Roche receives USFDA’s priority review to Xolair for food allergies based on positive NIH Phase III study results

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure

USFDA grants priority review for Patritumab Deruxtecan in US for certain patients with EGFR-mutated non-small cell lung cancer

If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients

FDA grants priority review to Merck’s new biologics license application for V116

V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults